EvolutionaryScale, founded in 2023 and headquartered in New York City, specializes in developing artificial intelligence models for protein design. Their flagship product, ESM3, is a generative language model trained on extensive biological data, enabling scientists to predict protein structures and design novel proteins with specific functions. In June 2024, EvolutionaryScale raised $142 million in seed funding led by Lux Capital, with participation from Amazon Web Services, NVentures, and angel investors Nat Friedman and Daniel Gross. The company collaborates with partners such as AWS and NVIDIA to make ESM3 accessible through various platforms, aiming to advance scientific discovery in fields like drug development and materials science. EvolutionaryScale is committed to responsible AI development, adhering to a framework that ensures ethical research and deployment of their models. As of February 2025, the company continues to innovate at the intersection of AI and life sciences, striving to transform biological research and its applications. (February 2025)